STEPHANY INDORF: Open Payments
NPI 1992254981 · RAVENNA, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$962 in 59 payments from 12 companies in 2025. Trend: 2023 $913 · 2024 $854 · 2025 $962
Food & beverage: $962
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 27 | $388 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $184 |
| QOL Medical, LLC | 3 | $86 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $60 |
| Aimmune Therapeutics, Inc. | 3 | $59 |
| Celltrion USA Inc. | 3 | $44 |
| Janssen Biotech, Inc. | 2 | $39 |
| Ferring Pharmaceuticals Inc. | 2 | $34 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Novo Nordisk Inc | 1 | $18 |
Products named: ENTYVIO, RINVOQ, LINZESS, Sucraid, SKYRIZI, XIFAXAN, ZENPEP, MAVYRET.
Industry payments across OH — which companies pay providers there.
